GALECTIN THERAPEUTICS INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-30.8M | $-47.0M | $-41.1M | $-38.8M | $-30.5M | $-23.5M | $-13.3M | $-13.9M |
| Depreciation & Amortization | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | $0 |
| Stock-Based Compensation | $1.7M | $2.4M | $2.3M | $2.9M | $2.1M | $1.8M | $1.7M | $4.4M |
| Net Cash from Operating Activities | $-23.9M | $-41.8M | $-33.0M | $-31.1M | $-24.3M | $-20.6M | $-10.8M | $-10.2M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | — | $0 |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $26.5M | $31.2M | $40.0M | $10.0M | $36.8M | $263.0K | $50.1M | $15.4M |
| Net Change in Cash | — | — | — | — | — | — | — | $5.2M |
| Free Cash Flow | — | — | — | — | — | — | — | — |